LIVIVO - Search results -

Search results

Result 1 - 10 of total 140

Search options

Article ; Online: Donors, donors, and more donors.

Anderlini, Paolo

2009 Volume 114, Issue 18, Page(s) 3721–3722

Language	English
Publishing date	2009-10-29
Publishing country	United States
Document type	Comment ; Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2009-08-239103
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effects and safety of granulocyte colony-stimulating factor in healthy volunteers.

Anderlini, Paolo

Current opinion in hematology

2008 Volume 16, Issue 1, Page(s) 35–40

Abstract: Purpose of review: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is now widely used in normal donors for collection of peripheral blood progenitor cells for allogeneic transplantation and granulocytes for transfusion. Currently ... ...

Abstract	Purpose of review: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is now widely used in normal donors for collection of peripheral blood progenitor cells for allogeneic transplantation and granulocytes for transfusion. Currently available data on biologic and molecular effects, and safety of rhG-CSF in normal healthy volunteers are reviewed. Recent findings: In addition to its known activating role on neutrophil kinetics and functional status, rhG-CSF administration can affect monocytes, lymphocytes and the hemostatic system. Granulocyte colony-stimulating factor receptors were identified in a variety of nonmyeloid tissues, although their role and functional activity have not always been well defined. Moreover, rhG-CSF is capable of modulating complex cytokine networks and can impact the inflammatory response. In addition to its known mobilizing role for peripheral blood progenitor cells, rhG-CSF can mobilize dendritic and endothelial progenitor cells as well. On a clinical level, serious rhG-CSF-related adverse events are well described (e.g. splenic rupture) but remain rare. Summary: rhG-CSF effects in healthy volunteers, although normally transient and self-limiting, are now believed to be more complex and heterogeneous than previously thought. Although rhG-CSF administration to healthy volunteers continues to have a favorable risk-benefit profile, these new findings have implications for safeguarding the safety of normal individuals.
MeSH term(s)	Chromosome Aberrations/drug effects ; Drug-Related Side Effects and Adverse Reactions ; Gene Expression Regulation/drug effects ; Granulocyte Colony-Stimulating Factor/adverse effects ; Granulocyte Colony-Stimulating Factor/pharmacology ; Hemostasis/drug effects ; Humans ; Immune System/drug effects ; Recombinant Proteins ; Stem Cells/drug effects
Chemical Substances	Recombinant Proteins ; Granulocyte Colony-Stimulating Factor (143011-72-7)
Language	English
Publishing date	2008-12-01
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1153887-9
ISSN	1531-7048 ; 1065-6251
ISSN (online)	1531-7048
ISSN	1065-6251
DOI	10.1097/MOH.0b013e328319913c
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3703: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.

Malek, Alexandre E / Al-Juhaishi, Taha / Milton, Denái R / Ramdial, Jeremy L / Daher, May / Olson, Amanda L / Srour, Samer A / Alatrash, Gheath / Oran, Betul / Mehta, Rohtesh S / Khouri, Issa F / Bashir, Qaiser / Shah, Nina / Ciurea, Stefan O / Rondon, Gabriela / Maadani, Farzaneh / Hosing, Chitra / Marin, David / Kebriaei, Partow /

Rezvani, Katayoun / Nieto, Yago / Anderlini, Paolo / Alousi, Amin M / Faisal, Muhammad Salman / Qazilbash, Muzaffar H / Popat, Uday R / Champlin, Richard E / Shpall, Elizabeth J / Mulanovich, Victor E / Ahmed, Sairah

Bone marrow transplantation

2024

Language	English
Publishing date	2024-02-14
Publishing country	England
Document type	Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-024-02238-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Surface Velocities and Strain-Rates in the Euro-Mediterranean Region From Massive GPS Data Processing

Enrico Serpelloni / Adriano Cavaliere / Leonardo Martelli / Francesco Pintori / Letizia Anderlini / Alessandra Borghi / Daniele Randazzo / Sergio Bruni / Roberto Devoti / Paolo Perfetti / Stefano Cacciaguerra

Frontiers in Earth Science, Vol

2022 Volume 10

Abstract: In this work we present and discuss new geodetic velocity and strain-rate fields for the Euro-Mediterranean region obtained from the analysis of continuous GNSS stations. We describe the procedures and methods adopted to analyze raw GPS observations from ...

Abstract	In this work we present and discuss new geodetic velocity and strain-rate fields for the Euro-Mediterranean region obtained from the analysis of continuous GNSS stations. We describe the procedures and methods adopted to analyze raw GPS observations from >4000 stations operating in the Euro-Mediterranean, Eurasian and African regions. The goal of this massive analysis is the monitoring of Earth’s crust deformation in response to tectonic processes, including plate- and micro-plate kinematics, geodynamics, active tectonics, earthquake-cycle, but also the study of a wide range of geophysical processes, natural and anthropogenic subsidence, sea-level changes, and hydrology. We describe the computational infrastructure, the methods and procedures adopted to obtain a three-dimensional GPS velocity field, which is used to obtain spatial velocity gradients and horizontal strain-rates. We then focus on the Euro-Mediterranean region, where we discuss the horizontal and vertical velocities, and spatial velocity gradients, obtained from stations that have time-series lengths longer than 6 and 7 years, which are found to be the minimum spans to provide stable and reliable velocity estimates in the horizontal and vertical components, respectively. We compute the horizontal strain-rate field and discuss deformation patterns and kinematics along the major seismogenic belts of the Nubia-Eurasia plate boundary zone in the Mediterranean region. The distribution and density of continuous GNSS stations in our geodetic solution allow us to estimate the strain-rate field at a spatial scale of ∼27 km over a large part of southern Europe, with the exclusion of the Dinaric mountains and Balkans.
Keywords	GNSS data processing ; time series analysis ; horizontal strain rates ; vertical ground velocities ; Euro-Mediterranean region ; Science ; Q
Subject code	551
Language	English
Publishing date	2022-06-01T00:00:00Z
Publisher	Frontiers Media S.A.
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.

Panch, Sandhya R / Logan, Brent / Sees, Jennifer A / Bo-Subait, Stephanie / Savani, Bipin / Shah, Nirali N / Hsu, Jack W / Switzer, Galen / Lazarus, Hillard M / Anderlini, Paolo / Hematti, Peiman / Confer, Dennis / Pulsipher, Michael A / Shaw, Bronwen E / Stroncek, David F

Transplantation and cellular therapy

2021 Volume 27, Issue 6, Page(s) 503.e1–503.e8

Abstract: Approximately 7% of unrelated hematopoietic stem cell donors are asked to donate stem cells a subsequent time to the same or a different recipient. Recent studies have shown that donation-related symptoms for second donations are similar to those for the ...

Abstract	Approximately 7% of unrelated hematopoietic stem cell donors are asked to donate stem cells a subsequent time to the same or a different recipient. Recent studies have shown that donation-related symptoms for second donations are similar to those for the first donation. Little is known about differences in stem cell mobilization and yields for subsequent peripheral blood stem cell (PBSC) and bone marrow (BM) collections. We hypothesized that CD34
MeSH term(s)	Cell Count ; Granulocyte Colony-Stimulating Factor ; Hematopoietic Stem Cell Mobilization ; Humans ; Peripheral Blood Stem Cells ; Unrelated Donors
Chemical Substances	Granulocyte Colony-Stimulating Factor (143011-72-7)
Language	English
Publishing date	2021-03-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2021.03.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Allogeneic peripheral blood stem cell collection as of 2008.

Rhodes, Beverly / Anderlini, Paolo

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

2008 Volume 38, Issue 3, Page(s) 219–227

Abstract: The rapid growth of the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to mobilize and collect allogeneic peripheral blood stem cells (PBSCs) for transplantation has made it a new international standard. While the procedure ... ...

Abstract	The rapid growth of the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to mobilize and collect allogeneic peripheral blood stem cells (PBSCs) for transplantation has made it a new international standard. While the procedure remains safe, older donors, donors with significant comorbidities and pediatric donors are now often employed. This brings a new set of challenges in the donor evaluation, medical clearance, informed consent and collection process. Rare and unexpected severe adverse events related to rhG-CSF administration and PBSC apheresis have been described. Proper PBSC donor counseling, evaluation and care have become even more important.
MeSH term(s)	Blood Component Removal/methods ; Donor Selection/methods ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Living Donors ; Peripheral Blood Stem Cell Transplantation ; Recombinant Proteins ; Stem Cells/cytology ; Transplantation, Autologous ; Transplantation, Homologous
Chemical Substances	Recombinant Proteins ; Granulocyte Colony-Stimulating Factor (143011-72-7)
Language	English
Publishing date	2008-05-22
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2046795-3
ISSN	1878-1683 ; 1473-0502
ISSN (online)	1878-1683
ISSN	1473-0502
DOI	10.1016/j.transci.2008.04.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1739: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case.

Davoudi, Setareh / Anderlini, Paolo / Fuller, Gregory N / Kontoyiannis, Dimitrios P

Mycopathologia

2014 Volume 178, Issue 5-6, Page(s) 465–470

Abstract: Invasive fungal infections remain major causes of infection-related mortality in hematopoietic stem cell transplantation (HSCT) patients. Mixed infections and multiple organ involvement have been reported in these patients. Here, we report a case of ... ...

Abstract	Invasive fungal infections remain major causes of infection-related mortality in hematopoietic stem cell transplantation (HSCT) patients. Mixed infections and multiple organ involvement have been reported in these patients. Here, we report a case of mixed Aspergillus and Mucorales infection involving the lungs, brain, spleen and bone in a HSCT patient with relapsed acute myeloid leukemia, who finally improved with triple antifungal therapy and neurosurgical evacuation of brain abscesses. She was put on lifelong secondary prophylaxis with posaconazole with excellent compliance and no sign of toxicity despite over 10 years of drug administration. Serial galactomannan measurements and positron emission tomography/computed tomography were used and were helpful for disease activity monitoring. This is an instructive case of long-term survival after a severe combined mould infection.
MeSH term(s)	Antifungal Agents/therapeutic use ; Aspergillosis/complications ; Aspergillosis/diagnosis ; Aspergillosis/drug therapy ; Aspergillosis/pathology ; Aspergillus/isolation & purification ; Bone Marrow/microbiology ; Bone Marrow/pathology ; Brain/microbiology ; Brain/pathology ; Chemoprevention/methods ; Coinfection/diagnosis ; Coinfection/drug therapy ; Coinfection/microbiology ; Coinfection/pathology ; Drug Monitoring ; Female ; Humans ; Lung/microbiology ; Lung/pathology ; Mannans/analysis ; Mucorales/isolation & purification ; Mucormycosis/complications ; Mucormycosis/diagnosis ; Mucormycosis/drug therapy ; Mucormycosis/pathology ; Spleen/microbiology ; Spleen/pathology ; Survivors ; Tomography, X-Ray Computed ; Treatment Outcome ; Young Adult
Chemical Substances	Antifungal Agents ; Mannans ; galactomannan (11078-30-1)
Language	English
Publishing date	2014-08-03
Publishing country	Netherlands
Document type	Case Reports ; Journal Article
ZDB-ID	391081-7
ISSN	1573-0832 ; 0369-299X ; 0301-486X ; 0027-5530
ISSN (online)	1573-0832
ISSN	0369-299X ; 0301-486X ; 0027-5530
DOI	10.1007/s11046-014-9785-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.99: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.

Frontiers in immunology

2022 Volume 13, Page(s) 1032397

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged recently as a standard of care treatment for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and several subtypes of B-cell non-Hodgkin lymphoma (NHL). However, its use ... ...

Abstract	Chimeric antigen receptor (CAR) T-cell therapy has emerged recently as a standard of care treatment for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and several subtypes of B-cell non-Hodgkin lymphoma (NHL). However, its use remains limited to highly specialized centers, given the complexity of its administration and its associated toxicities. We previously reported our experience in using a novel Sleeping Beauty (SB) CD19-specific CAR T-cell therapy in the peri-transplant setting, where it exhibited an excellent safety profile with encouraging survival outcomes. We have since modified the SB CD19 CAR construct to improve its efficacy and shorten its manufacturing time. We report here the phase 1 clinical trial safety results. Fourteen heavily treated patients with relapsed/refractory ALL and NHL were infused. Overall, no serious adverse events were directly attributed to the study treatment. Three patients developed grades 1-2 cytokine release syndrome and none of the study patients experienced neurotoxicity. All dose levels were well tolerated and no dose-limiting toxicities were reported. For efficacy, 3 of 8 (38%) patients with ALL achieved CR/CRi (complete remission with incomplete count recovery) and 1 (13%) patient had sustained molecular disease positivity. Of the 4 patients with DLBCL, 2 (50%) achieved CR. The SB-based CAR constructs allow manufacturing of targeted CAR T-cell therapies that are safe, cost-effective and with encouraging antitumor activity.
MeSH term(s)	Humans ; Adaptor Proteins, Signal Transducing ; Antigens, CD19 ; B-Lymphocytes ; Hematologic Neoplasms/etiology ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Neoplasms/drug therapy ; Receptors, Antigen, T-Cell/genetics
Chemical Substances	Adaptor Proteins, Signal Transducing ; Antigens, CD19 ; Receptors, Antigen, T-Cell
Language	English
Publishing date	2022-11-10
Publishing country	Switzerland
Document type	Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2022.1032397
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement.

Akin, Serkan / Hosing, Chitra / Khouri, Issa / Ahmed, Sairah / Alousi, Amin / Fowler, Nathan / Joseph, Jacinth / Truxillo, Jonathan / Ramdial, Jeremy L / Maadani, Farzaneh / Rondon, Gabriela / Daher, May / Im, Jin S / Steiner, Raphael / Westin, Jason / Iyer, Swaminathan P / Dabaja, Bouthaina / Anderlini, Paolo / Popat, Uday R /

Qazilbash, Muzaffar H / Flowers, Christopher R / Shpall, Elizabeth / Champlin, Richard E / Nieto, Yago / Srour, Samer A

Blood advances

2022 Volume 6, Issue 7, Page(s) 2267–2274

Abstract: Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these high-risk patients. We explored in this study treatment ... ...

Abstract	Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these high-risk patients. We explored in this study treatment outcomes and prognostic factors for patients with SCNSL who underwent ASCT. We included all consecutive patients who underwent ASCT at our institution. Primary endpoints were progression-free survival (PFS) and overall survival (OS). One-hundred two patients were identified. Median age at transplant was 56 (range, 21-71) years. With a median follow-up of 56 (range, 1-256) months, the median PFS and OS were 40 and 88 months, respectively. The 4-year PFS and OS were 48% and 57%, respectively. In univariate analysis, complete remission (CR) at transplant, prior lines of therapy (≤2), normal lactate dehydrogenase, and parenchymal involvement were significantly associated with improved PFS. For OS, only CR at transplant and ≤2 prior lines of therapy were associated with improved survival. On multivariable analysis for PFS, CR at transplant (hazard ratio [HR], 0.278; 95% CI, 0.153-0.506; P ≤ .0001) and ≤2 prior lines of therapy (HR, 0.485; 95% CI, 0.274-0.859; P = .0131) were significantly associated with superior PFS. Similarly, CR at transplant (HR, 0.352; 95% CI, 0.186-0.663; P = .0013) and ≤2 prior lines of therapy (HR, 0.476; 95% CI, 0.257-0.882; P = .0183) were associated with improved survival. In the largest single-center study, our findings indicate that ASCT is associated with durable responses and prolonged survival in patients with SCNSL. Patients in CR at transplant and those who received ≤2 lines of therapy have particularly excellent outcomes.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Central Nervous System ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Large B-Cell, Diffuse/therapy ; Transplantation, Autologous
Language	English
Publishing date	2022-01-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2021005602
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.

Transplantation and cellular therapy

2022 Volume 28, Issue 7, Page(s) 395.e1–395.e11

Abstract: With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched related donor hematopoietic cell transplantation (HCT) are now approaching those of matched donor HCT. Here we compared haploidentical donor HCT versus HLA-matched ... ...

Abstract	With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched related donor hematopoietic cell transplantation (HCT) are now approaching those of matched donor HCT. Here we compared haploidentical donor HCT versus HLA-matched unrelated donor (MUD) HCT and HLA-identical sibling donor (MSD) HCT in a cohort in which all patients received PTCy for graft-versus-host disease (GVHD) prophylaxis. We included 661 patients (275 haploidentical, 246 MUD, and 140 MSD HCT). The most common diagnoses were acute myelogenous leukemia and myelodysplastic syndrome. In multivariate analysis, the haploidentical group was found to have significantly higher nonrelapse mortality (NRM) (hazard ratio [HR], 3.2; 95% confidence interval [CI], 2 to 4.9; P < .001) and inferior progression-free survival (HR, 1.8; 95% CI, 1.4 to 2.4; P < .001) and overall survival (OS; HR, 2.2; 95% CI, 1.6 to 3; P < .001) compared with the MUD group. Relapse was the most common cause of death in all groups. Among causes of NRM, the haploidentical group had more infection-related deaths and fewer GVHD-related deaths than the other groups. The haploidentical group also had a higher risk of viral and fungal infections, grade ≥3 hemorrhagic cystitis, and cardiovascular toxicities and slower reconstitution of CD4, CD8, and regulatory T cells but faster reconstitution of natural killer cells. In an exploratory analysis, older patients with older donors (>50 years for both) appeared to have particularly high NRM and lower OS in the haploidentical group compared with the other groups. Our data suggest that even with the use of PTCy, the outcomes of haploidentical HCT are inferior to those of HLA-matched donor HCT.
MeSH term(s)	Cyclophosphamide/therapeutic use ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Siblings ; Transplantation Conditioning ; Transplantation, Haploidentical
Chemical Substances	Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2022-05-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2022.04.020
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito